Education
About Us
Working with TipRanks
Follow Us
C4 Therapeutics (CCCC)
NASDAQ:CCCC
CCCC Stock Chart & Stats
$2.70
-$0.05(-1.30%)
At close: 4:00 PM EST
$2.70
-$0.05(-1.30%)
Day’s Range― - ―
52-Week Range$1.09 - $3.65
Previous CloseN/A
Volume165.25K
Average Volume (3M)1.78M
Market Cap
$309.32M
Enterprise Value$211.01M
Total Cash (Recent Filing)$248.54M
Total Debt (Recent Filing)$59.98M
Price to Earnings (P/E)―
Beta2.27
Next Earnings
May 13, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding97,578,180
10 Day Avg. Volume2,703,770
30 Day Avg. Volume1,780,246
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)0.62
Price to Sales (P/S)4.40
P/FCF Ratio-1.59
Enterprise Value/Market Cap0.68
Enterprise Value/Revenue5.87
Enterprise Value/Gross Profit6.18
Enterprise Value/Ebitda-1.95
Forecast
1Y Price Target
$12.75Price Target Upside372.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.09
Revenue Forecast (FY)$21.62M
Bulls Say, Bears Say
Bulls Say
Proprietary TORPEDO Targeted Protein Degradation PlatformA proprietary discovery platform focused on targeted protein degradation is a durable competitive asset: it supports repeated R&D programs, increases the chance of first-in-class assets across indications, and strengthens partnership appeal to large pharmas seeking new modalities.
Defined Multi-year Cemsidomide Clinical Strategy And PartnershipsA published multi-year clinical roadmap and named collaborations provide structural de-risking: clear milestone sequencing, validation from partners, and a stated cash runway through 2028 materially increase the company’s ability to execute pivotal programs without immediate financing.
Demonstrable Clinical Progress: Phase 1 Activity And Phase 2 InitiationEarly clinical efficacy signals paired with advancement into Phase 2 represent durable program-level validation: they support regulatory pathway planning, enable combination trials, and create multiple clinical catalysts that can convert platform science into potential commercial-stage assets.
Bears Say
No Commercial Revenue In 2025 And Persistent LossesThe absence of meaningful commercial revenue means the business remains pre-revenue and dependent on capital markets, partnerships, or milestones. Persistent operating losses reduce internal reinvestment capacity and increase the probability of future financing and dilution if clinical progress stalls.
Sustained High Cash Burn And Negative Free Cash FlowConsistently negative OCF and FCF at scale create ongoing funding pressure: even with stated runway, continued burn magnifies financing risk, can force prioritization or program cuts, and limits margin sustainability until revenue and profitability are achieved.
Inherent Clinical And Regulatory Execution RiskValue is concentrated in clinical outcomes; trial delays, negative readouts, or regulatory setbacks can materially reduce asset value. Even with platform and partners, biotech execution risk remains structural and can negate pipeline and partnership benefits over the medium term.
C4 Therapeutics News
CCCC FAQ
What was C4 Therapeutics’s price range in the past 12 months?
C4 Therapeutics lowest stock price was $1.08 and its highest was $3.65 in the past 12 months.
What is C4 Therapeutics’s market cap?
C4 Therapeutics’s market cap is $309.32M.
When is C4 Therapeutics’s upcoming earnings report date?
C4 Therapeutics’s upcoming earnings report date is May 13, 2026 which is in 70 days.
How were C4 Therapeutics’s earnings last quarter?
C4 Therapeutics released its earnings results on Feb 26, 2026. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.288 by $0.108.
Is C4 Therapeutics overvalued?
According to Wall Street analysts C4 Therapeutics’s price is currently Undervalued.
Does C4 Therapeutics pay dividends?
C4 Therapeutics does not currently pay dividends.
What is C4 Therapeutics’s EPS estimate?
C4 Therapeutics’s EPS estimate is -0.27.
How many shares outstanding does C4 Therapeutics have?
C4 Therapeutics has 97,578,180 shares outstanding.
What happened to C4 Therapeutics’s price movement after its last earnings report?
C4 Therapeutics reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.288. Following the earnings report the stock price went up 0.361%.
Which hedge fund is a major shareholder of C4 Therapeutics?
Currently, no hedge funds are holding shares in CCCC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
C4 Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.75 (372.22% Upside)
$12.75 (372.22% Upside)
Blogger Sentiment
Neutral
CCCC Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 8.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $22.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 1.8%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
News Sentiment
Very Bullish
Bullish news 83%
Bearish news 17%
Bearish news 17%
Technicals
SMA
Negative
20 days / 200 days
Momentum
3.84%
12-Months-Change
Fundamentals
Return on Equity
-44.44%
Trailing 12-Months
Asset Growth
6.39%
Trailing 12-Months
Company Description
C4 Therapeutics
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
CCCC Stock 12 Month Forecast
Average Price Target
$12.75
▲(372.22% Upside)
Technical Analysis
SELLAS Life Sciences Group
―
Seres Therapeutics
―
Eledon Pharmaceuticals
―
Tevogen Bio Holdings
―
Actuate Therapeutics, Inc.
―
Ownership Overview
1.64% Insiders
8.63% Mutual Funds
11.32% Other Institutional Investors
72.54% Public Companies and
Individual Investors